ArticleBiomarker research2026
Tumor-enriched circRNA TAFCR1 drives cancer progression and metastasis by disrupting UBE1-dependent TRIM21-mediated CD44 ubiquitination.
Article in Biomarker research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Lipid metabolic reprogramming is a hallmark of cancer, driving tumorigenesis, progression, metastasis, and chemoresistance. Fatty acid synthase (FASN) is a key enzyme in this pathway. Here, we identified a novel exonic circular RNA (circRNA) within the FASN locus, termed TAFCR1 (tumor-associated FASN circular RNA 1). TAFCR1 comprises partial exon 20 (20 L), exons 21, 22, and partial 23 (23 S) of the FASN gene, generated through MBNL1-mediated back-splicing via short Alu motifs at the cyclization junction. TAFCR1 was tumor-specifically upregulated and promoted proliferation, invasion, and migration of cancer cells in vitro. In vivo, TAFCR1 knockdown suppressed tumor growth and metastasis, and prolonging survival in xenograft and lung metastasis models. Mechanistically, TAFCR1 functions as a specific RNA modulator that binds the ubiquitin-activating enzyme E1 (UBE1/UBA1), thereby disrupting UBE1-dependent, TRIM21-mediated CD44 ubiquitination and upregulating the oncogenic signaling molecule CD44. The E3 ubiquitin ligase TRIM21 serves as a critical mediator regulating CD44 ubiquitination by binding to the CD44 intracellular domain (CD44-ICD) and catalyzing K48-linked polyubiquitination of CD44 at K695. Upregulated CD44 further activates the PI3K/AKT pathway by suppressing the tumor suppressor PHLPP1. This cascade subsequently enhances the expression of stemness factor SOX2, epithelial-mesenchymal transition (EMT) markers (vimentin, N-cadherin, and fibronectin), and matrix metalloproteinase-9 (MMP9), ultimately promoting cancer metastasis. Collectively, our findings establish TAFCR1 as a promising therapeutic target for cancers.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.